Blenrep (Belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple Myeloma

CAR-T Digest - August 2020

17 Apr 2025: Blenrep (Belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple Myeloma

UK MHRA approved Blenrep (Belantamab mafodotin) in combination therapies for relapsed/refractory multiple Myeloma, marking the first global authorization for its use in earlier lines of treatment
Blenrep showed superior efficacy in two Phase 3 trials (DREAMM-7 and DREAMM-8) with significant improvements in progression-free survival (PFS) and overall survival (OS) compared to standard of care, including nearly tripled median PFS in DREAMM-7
The combinations demonstrated benefits across a broad patient population, including those with high-risk features or prior resistance to Lenalidomide, with manageable safety profiles and low treatment discontinuation rates due to side effects
Blenrep is the only BCMA-targeted antibody-drug conjugate (ADC) for multiple myeloma, offering a new mechanism of action without the need for complex pre-treatment or hospitalisation
Regulatory submissions for Blenrep combinations are underway in 14 other countries, with further global approvals expected in 2025, including in the US, EU, Japan, China, and Canada